RarePlex® Synaptophysin CTC Panel Kit

RarePlex – Staining Kits
Panel Kits – Enumeration | ARv7 | SYP | ARv7/SYP | HER2/ER | PD-L1
Developer Kits – 405/488
Download Datafiles

RarePlex Synaptophysin CTC Panel Kit

Tumor expression of Synaptophysin in cancer is an indicator of neuro-endocrine differentiation, a prominent mechanism by which tumors become resistant to therapies. The RarePlex 0920-VB Synaptophysin CTC Panel Kit enables immunofluorescent detection of Synaptophysin (SYP) expression by epithelial circulating tumor cells (CTCs).  Analysis of CTCs via blood allows for a less-invasive method to identify cancer cells and can prove helpful in prognosis, treatment selection, patient stratification, and monitoring. 

With the flexibility of one open channel, the RarePlex Synaptophysin CTC Panel Kit expands clinical research of therapeutic resistance by combining SYP with any other marker of your interest. This assay is designed for use with the AccuCyte® Sample Preparation System and the CyteFinder® Instrument for a blood-to-result solution.

Analytic validation studies* using spike-in SYP+ and SYP- cancer cell lines as model CTCs (mCTCs) have demonstrated the RarePlex Synaptophysin CTC Panel Kit to be highly specific, sensitive and accurate:

  • SYP biomarker Accuracy of 99%
  • SYP biomarker Sensitivity of 99%
  • SYP biomarker Specificity of 100%

*Studies were performed using quantitative mean fluorescence intensity measurements of mCTCs

The kit contains a nuclear dye; a panel of antibodies and reagents for detection of CD45 (to exclude WBC), Cytokeratin and EpCAM, and Synaptophysin; instructions and protocols for automated staining and scanning; and guidelines for interpreting results. 


22RV1 stained with the 0920-VB Synaptophysin CTC Panel Kit.
Scale bar represents 10μm.
Distribution of SYP MFI for mCTC across 5 slide replicates per cell line for stainer run 1 (left), 2, (center), and 3 (right). Whiskers indicate the 10-90 percentile range. Dotted lines indicate thresholds (MFI=140 for SYP) used to determine biomarker expression status on a per-cell basis.